Stefan Galluppi Buys 3,000 Shares of LifeMD, Inc. (NASDAQ:LFMD) Stock

LifeMD, Inc. (NASDAQ:LFMD) insider Stefan Galluppi purchased 3,000 shares of the stock in a transaction that occurred on Wednesday, September 11th. The stock was bought at an average cost of $4.93 per share, with a total value of $14,790.00. Following the acquisition, the insider now owns 45,449 shares of the company’s stock, valued at $224,063.57. The acquisition was disclosed in a document filed with the SEC, which is available at the SEC website.

LifeMD Stock Up 0.8 %

LifeMD stock opened at $5.27 on Friday. The firm has a market capitalization of $226.98 million, a price-to-earnings ratio of -7.12 and a beta of 1.19. The company’s 50 day simple moving average is $5.80 and its 200 day simple moving average is $7.92. The company has a debt-to-equity ratio of 10.83, a current ratio of 0.87 and a quick ratio of 0.83. LifeMD, Inc. has a fifty-two week low of $4.05 and a fifty-two week high of $12.88.

LifeMD (NASDAQ:LFMD) last announced its quarterly earnings results on Wednesday, August 7th. The company reported ($0.19) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.13) by ($0.06). The firm had revenue of $50.66 million for the quarter, compared to the consensus estimate of $48.47 million. During the same period last year, the business earned ($0.23) earnings per share. As a group, sell-side analysts anticipate that LifeMD, Inc. will post -0.49 EPS for the current year.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in LFMD. ClariVest Asset Management LLC boosted its holdings in shares of LifeMD by 2.9% in the 2nd quarter. ClariVest Asset Management LLC now owns 91,967 shares of the company’s stock valued at $631,000 after buying an additional 2,600 shares during the last quarter. Quest Partners LLC bought a new position in shares of LifeMD in the 2nd quarter valued at about $31,000. Deerfield Management Company L.P. Series C raised its holdings in shares of LifeMD by 25.6% in the 2nd quarter. Deerfield Management Company L.P. Series C now owns 40,289 shares of the company’s stock valued at $276,000 after purchasing an additional 8,204 shares during the period. EntryPoint Capital LLC bought a new stake in shares of LifeMD in the 1st quarter valued at about $89,000. Finally, Los Angeles Capital Management LLC acquired a new stake in LifeMD in the 2nd quarter valued at about $88,000. Institutional investors and hedge funds own 35.52% of the company’s stock.

Wall Street Analyst Weigh In

LFMD has been the subject of several research reports. B. Riley started coverage on LifeMD in a research note on Friday, August 23rd. They issued a “buy” rating and a $11.00 target price for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $15.00 price objective on shares of LifeMD in a report on Tuesday, August 20th. Finally, KeyCorp reduced their target price on shares of LifeMD from $12.00 to $10.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Six research analysts have rated the stock with a buy rating, Based on data from MarketBeat, LifeMD has a consensus rating of “Buy” and an average price target of $12.00.

LifeMD Company Profile

LifeMD, Inc operates as a direct-to-patient telehealth company that connects consumers to healthcare professionals for medical care in the United States. The company offers telehealth platform comprising RexMD, a men's telehealth brand that provides access to virtual medical treatment for a variety of men's health needs from licensed physician; ShapiroMD that provides virtual medical treatment, prescription medications, patented doctor formulated OTC products, topical compounded medications, and medical devices treating male and female hair loss; NavaMD, a female-oriented tele-dermatology that offers virtual medical treatment from dermatologists and other providers; and prescription oral and compounded topical medications to treat aging and acne; and Cleared which provides personalized treatments for allergy, asthma and immunology, including in-home tests for both environmental and food allergies, prescriptions for allergies and asthma and immunotherapies for treating chronic allergies.